Alloferon

Primary Application: Immune System Enhancement and Antiviral/Antitumor Research

Fundamental Information

• Amino Acid Sequence: His-Gly-Val-Ser-Gly-His-Gly-Gln-His-Gly-Val-His-Gly (Alloferon 1)

• Molecular Weight: 1265.3 Daltons

• Source: Originally isolated from the Blowfly (Calliphora vicina)

• Classification: NK Cell Stimulating Peptide

Detailed Overview

Alloferon is a natural immunomodulatory peptide with a unique historical discovery rooted in “biosurgery” or maggot therapy. For centuries, military surgeons—including Dominique-Jean Larrey during Napoleon’s Syrian campaign and William Baer during World War I—observed that wounds infested with blue blowfly larvae healed remarkably fast and without infection. Decades of subsequent research by Russian scientist Sergey Chernysh revealed that these larvae possess a powerful immune system that synthesizes unique antiviral and antitumor factors. Alloferon was first isolated from the blood of these larvae following experimental bacterial infection.

The name “Alloferon” reflects its role as an invertebrate-derived peptide (Allo) that functions similarly to the mammalian interferon (feron) system. Its primary biological activity is the upregulation of the 2B4 (CD244) receptor on Natural Killer (NK) cells. This triggers a specific signaling pathway (likely through the NF-kB pathway) that encourages NK cells to release “killing tools” like perforin and granzyme B, which physically destroy virus-infected or cancerous cells.

Alloferon is an immune-boosting peptide that acts as a “natural alarm” for the body’s defense system. It works by specifically activating Natural Killer (NK) cells—the white blood cells responsible for hunting down and destroying viruses and tumor cells. Alloferon binds to these cells and triggers the upregulation of 2B4 (CD244) activating receptors. This signals the cells to produce more “killing tools” like perforin and granzyme B, which allow the immune system to physically destroy compromised or infected cells.

In various studies, Alloferon has demonstrated the ability to significantly slow the growth of tumors and reduce the viral load of persistent infections like Herpes (HHV-1) and Epstein-Barr (EBV). It essentially mimics the behavior of interferon, the body’s primary anti-infection signal, but without the harsh side effects often seen with synthetic treatments. Researchers are currently using it to explore new ways to strengthen the “innate” immune system to handle both oncology and chronic viral loads.

In Russia, Alloferon is clinically approved under the trade name Allokin-Alpha for treating chronic infections such as Human Papillomavirus (HPV), Herpes Simplex (HSV 1/2), and Hepatitis B/C. Clinical trials have demonstrated an elimination rate of HPV in up to 90% of cases when used alongside standard treatments. Because it is a short peptide of only 13 amino acids, it does not provoke the allergic reactions common with larger protein drugs, and it is researched for its ability to strengthen the body’s “innate” defense without the toxicity of synthetic antivirals.

Scientific References

1. Chernysh S, et al. “Antitumor and antiviral peptides from blow fly (Calliphora vicina) larvae.” Proc Natl Acad Sci USA. 2002;99(20):12628-32.

2. Kim SA, et al. “The effect of alloferon on the enhancement of NK cell cytotoxicity against cancer via the up-regulation of perforin/granzyme B secretion.” Immunobiology. 2013;218(3):328-35.

3. Rakitianskaya IA, et al. “Allokin-alpha – new approaches in the treatment of chronic virus Epstein-Barr infections.” Problems of Virology. 2019;64(3):118-124.